Related Experiment Videos
Anticonvulsant effects of bretazenil (Ro 16-6028) during ontogenesis
H Kubová1, J Rathouská, P Mares
1Institute of Physiology, Czechoslovak Academy of Sciences, Prague.
Insights
Bretazenil (Ro 16-6028) demonstrated dose-dependent anticonvulsant effects against metrazol-induced seizures in rats of various ages. The drug was most effective in suppressing major seizures, particularly in younger animals.
Area of Science:
- Neuroscience
- Pharmacology
- Developmental Biology
Background:
- Benzodiazepines are commonly used as anticonvulsants.
- Bretazenil (Ro 16-6028) is a novel benzodiazepine with potential anticonvulsant properties.
- Seizure susceptibility and drug response can vary with age.
Purpose of the Study:
- To investigate the anticonvulsant effects of bretazenil (Ro 16-6028) in a rat model.
- To evaluate the influence of age on bretazenil's efficacy against seizures.
Main Methods:
- 240 rats across five age groups (7, 12, 18, 25, 90 days) were used.
- Metrazol (pentamethylenetetrazol, PTZ) was administered to induce minimal and major motor seizures.
- Animals were pretreated with varying doses of bretazenil (0.001-0.1 mg/kg) before PTZ administration.
Main Results:
- Bretazenil suppressed both minimal and major metrazol-induced seizures in a dose-dependent manner.
- Major seizures were more sensitive to bretazenil than minimal seizures across all age groups.
- Youngest rats (7 and 12 days old) showed maximal effects against major seizures, but bretazenil increased minimal seizures in these age groups.
Conclusions:
- Bretazenil exhibits significant anticonvulsant activity against PTZ-induced seizures in rats.
- Age plays a crucial role in the efficacy and specific effects of bretazenil.
- Further research is warranted to understand the age-dependent mechanisms of bretazenil's action.
Abstract:
Anticonvulsant action of a new benzodiazepine, bretazenil (Ro 16-6028), was studied in 240 rats in five age groups: age 7, 12, 18, 25 and 90 days. Motor seizures induced by metrazol (pentamethylenetetrazol, PTZ, 100 mg/kg subcutaneously (s.c.) except for 18-day-old rats which received a dose of 90 mg/kg) served as a model. Animals were pretreated with Ro 16-6028 in doses of 0.001-0.1 mg/kg intraperitoneally (i.p.) 10 min before metrazol. Both types of metrazol-induced seizures, minimal (mMS, predominantly clonic with preserved righting ability) and major (MMS, generalized tonic-clonic), were suppressed by Ro 16-6028 in a dose-dependent manner. Major seizures were always more sensitive to Ro 16-6028 than were minimal seizures. The youngest rats exhibited maximal effects of Ro 16-6028 against major seizures. On the other hand, this drug increased the incidence of minimal seizures in 7- and 12-day-old rats, i.e., in age groups in which this type of seizure is rare under control conditions.